SCHEMBL786744 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	FADS1	O60427	2/20	0.45

▸	EGFR	P00533	2/20	0.42

▸	GSK3A	P49840	3/20	0.41

▸	GSK3B	P49841	3/20	0.41

▸	ACHE	P22303	4/20	0.38

▸	BCHE	P06276	3/20	0.38

▸	GRIN1	Q05586	3/20	0.38

▸	GRIN2A	Q12879	3/20	0.38

▸	IGF1R	P08069	1/20	0.38

▸	KDM4E	B2RXH2	1/20	0.37

▸	NPC1	O15118	1/20	0.37

▸	ALDH1A1	P00352	1/20	0.37

▸	LMNA	P02545	1/20	0.37

▸	GAA	P10253	1/20	0.37

▸	MAPT	P10636	1/20	0.37

▸	HPGD	P15428	1/20	0.37

▸	RAB9A	P51151	1/20	0.37

▸	RIPK2	O43353	1/20	0.36

▸	SOS1	Q07889	1/20	0.36

▸	NTRK1	P04629	1/20	0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL786233	0.97	FADS1 (0.46)	FADS1EGFRGSK3AGSK3BACHE
SCHEMBL13107334	0.89	EGFR (0.42)	FADS1EGFRGSK3AGSK3BACHE
SCHEMBL786366	0.88	TRPA1 (0.43)	FADS1EGFRACHEIGF1RKDM4E
SCHEMBL10150027	0.88	FADS1 (0.44)	FADS1EGFRGSK3AGSK3BMAPT
SCHEMBL785480	0.87	USP1 (0.45)	FADS1EGFRGSK3AGSK3BIGF1R
SCHEMBL802419	0.87	EGFR (0.43)	FADS1EGFRGSK3AGSK3BACHE
SCHEMBL12653892	0.87	EGFR (0.41)	FADS1EGFRGSK3AGSK3BACHE
SCHEMBL786128	0.87	USP1 (0.45)	FADS1EGFRGSK3AGSK3BIGF1R
SCHEMBL785418	0.86	EGFR (0.41)	EGFRGSK3AGSK3BACHEBCHE
SCHEMBL785653	0.86	USP1 (0.46)	FADS1EGFRGSK3AGSK3BIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-20110224197-A1	PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-09-15	—	—	US	disclosed
US-20110224197-A1	PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-09-15	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-10-07	—	—	US	disclosed
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-10-07	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7473691-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-01-06	—	—	US	disclosed
US-7473691-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-01-06	—	—	US	disclosed
US-7390815-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2008-06-24	—	—	US	disclosed
US-7390815-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2008-06-24	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, CDK3, GSK3A	FADS1 1449/4885EGFR 305/4885GSK3A 3/4885
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, GSK3A, CDK19	FADS1 3442/4885EGFR 154/4885GSK3A 2/4885
US-20110224197-A1	PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES	GSK3B, CDK3, GSK3A	FADS1 2602/4885EGFR 1514/4885GSK3A 3/4885
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	GSK3B, CDK3, GSK3A	FADS1 1449/4885EGFR 305/4885GSK3A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.